Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
701 (USA) · Dr. Reyes
consented 2013-12-05
AEs
1
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Moderate AGITATION — outcome: RECOVERED/RESOLVED; onset 2013-12-09 (study day 5.0); relationship: NONE
Data queries
No data queries.